Bernstein Research Highlights Structural Growth for Carl Zeiss Meditec Amid Share Price Weakness

Bernstein Research maintains a Market-Perform rating and €28.50 target for Carl Zeiss Meditec, citing long-term medtech trends and a 2026 dividend, despite shares trading near a 52-week low.

Investors in Carl Zeiss Meditec have been searching for positive catalysts following an extended period of downward pressure on its shares. A fresh industry analysis from Bernstein Research now provides a clear framework for evaluating the medical technology firm's prospects. The research firm has reaffirmed its assessment of the company and outlined several fundamental drivers expected to support growth in the coming years.

Upcoming Dividend Provides Tangible Return

Beyond analyst commentary, a specific capital distribution is approaching for shareholders. The company has declared a dividend payment of 0.55 euros per share for the concluded fiscal year. The ex-dividend date is set for Friday, March 27, 2026, with the payment scheduled to reach shareholder accounts on March 31. This forthcoming distribution offers a concrete financial return during a phase of persistent market softness for the equity.

Analyst Maintains Rating with Defined Price Target

Bernstein analyst Susannah Ludwig has maintained a "Market-Perform" rating on the stock. Her analysis simultaneously establishes a price target of 28.50 euros. This valuation is primarily grounded in long-term sector trends. A consistently aging global population is creating a structurally rising demand for medical care and associated technology.

Furthermore, the expansion into new geographical markets that currently show low penetration rates presents substantial revenue opportunities. For the broader European medtech sector, the U.S.-based research firm projects average growth in the mid-single-digit percentage range.

Shares Trade Near Annual Low

This analytical optimism, however, is not yet reflected in the stock's market performance. Since the start of the year, the share price has declined by 40.09 percent. Closing at 23.64 euros in the previous session, the equity is trading just marginally above its recently established 52-week low of 23.52 euros. Within this heavily depressed trading environment, Bernstein's stated price target implies a significant theoretical premium to the current valuation level.